Guardant Health, Inc. (FRA:5GH)

Market Cap	11.43B +102.5%
Revenue (ttm)	836.39M +32.9%
Net Income	-354.54M
EPS	-2.83
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	37
Open	93.04
Previous Close	90.94
Day's Range	93.04 - 93.04
52-Week Range	32.52 - 99.94
Beta	n/a
RSI	54.63
Earnings Date	Feb 19, 2026

About Guardant Health

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that p...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2011
• Employees: 2,010
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5GH

Financial Performance

In 2025, Guardant Health's revenue was $982.02 million, an increase of 32.88% compared to the previous year's $739.02 million. Losses were -$416.28 million, -4.61% less than in 2024.

Financial numbers in USD